title: Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib.
abstract: BACKGROUND
  This study investigated whether the effectiveness of first-line tyrosine-kinase inhibitors was associated with sites of disease in patients with metastatic renal cell carcinoma (mRCC).
  
  
  METHODS
  A retrospective cohort of consecutive mRCC patients receiving first-line sorafenib (SO) or sunitinib (SU) was analyzed.
  
  
  RESULTS
  In total, 203 patients received SO and 99 SU. In patients with liver metastasis, SU was associated with a 18% higher risk of time-to-treatment failure (TTF), and a 39% higher risk of death than SO: conversely, patients without liver metastases who received SU showed a 46% decreased risk of TTF and 62% decreased risk of death.
  
  
  CONCLUSIONS
  mRCC patients with liver metastases treated with first-line SO showed a better outcome compared with SU, while mRCC patients without liver metastases treated with first-line SU showed a better outcome compared with SO.
authors.affiliation: Medical Oncology 1, Fondazione IRCCS, Istituto Nazionale Tumori, Via G. Venezian 1, Milan, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Grassi
authors.affiliation: Medical Oncology 1, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Verzoni
authors.affiliation: Laboratory of Methodology for Biomedical Research, Oncology Department, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Porcu
authors.affiliation: Medical Oncology 1, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Iacovelli
authors.affiliation: Medical Oncology 1, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.
authors.forename: Filippo
authors.initials: F
authors.lastname: de Braud
authors.affiliation: Medical Oncology 1, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Procopio
keywords: predictive factors; renal cell carcinoma; sites of metastases; sorafenib; sunitinib
references.citation: J Clin Oncol. 2008 Oct 1;26(28):4572-8
references.pmid: 18824708
references.citation: N Engl J Med. 2007 Jan 11;356(2):115-24
references.pmid: 17215529
references.citation: J Clin Oncol. 2009 Dec 1;27(34):5794-9
references.pmid: 19826129
references.citation: N Engl J Med. 2007 Jan 11;356(2):125-34
references.pmid: 17215530
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: J Natl Cancer Inst. 2011 May 4;103(9):763-73
references.pmid: 21527770
references.citation: JAMA. 2006 Jun 7;295(21):2516-24
references.pmid: 16757724
references.citation: J Clin Oncol. 1999 Aug;17(8):2530-40
references.pmid: 10561319
references.citation: Eur Urol. 2014 Mar;65(3):577-84
references.pmid: 23962746
references.citation: J Exp Clin Cancer Res. 2010 Jul 14;29:95
references.pmid: 20630084
references.citation: Lancet. 2011 Dec 3;378(9807):1931-9
references.pmid: 22056247
references.citation: Lancet Oncol. 2012 Aug;13(8):827-37
references.pmid: 22759480
references.citation: BMC Cancer. 2014 Jun 02;14:390
references.pmid: 24885730
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1280-9
references.pmid: 19171708
references.citation: J Clin Oncol. 2012 Sep 20;30(27):3402-7
references.pmid: 22891270
references.citation: Clin Cancer Res. 2011 Sep 15;17 (18):6021-8
references.pmid: 21742806
references.citation: Lancet Oncol. 2009 Aug;10 (8):757-63
references.pmid: 19615940
references.citation: Acta Oncol. 2008;47(2):176-86
references.pmid: 18210295
references.citation: Clin Cancer Res. 2010 Feb 15;16(4):1216-25
references.pmid: 20145174
references.citation: Ann Oncol. 2002 Sep;13(9):1460-8
references.pmid: 12196373
references.citation: Ann Oncol. 2012 Apr;23(4):973-80
references.pmid: 21890909